Brought to you by 
Infinity signs deal with J&JPRD for small-molecule drugs
29 Aug 2006
Executive Summary
In its second deal in just as many days, Infinity Pharmaceuticals (small-molecule cancer therapeutics) has signed an agreement covering the use of its compound collection. This small-molecule deal gives Johnson & Johnson Pharmaceutical R&D a non-exclusive license to the library against which J&JPRD can screen multiple targets and perform chemistry activities to identify drug leads.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Infinity signs deal with J&JPRD for small-molecule drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice